[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 714 pages | ID: UEB8F3FBB5ACEN
Global Markets Direct

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 20, 51, 51, 3, 100, 30 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 11 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ulcerative Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 18, 2022: Prometheus Biosciences completes enrollment of the ARTEMIS-UC cohort 1 phase 2 study in ulcerative colitis
Jul 07, 2022: Biora Therapeutics announces successful completion of second device performance study in human subjects for its targeted therapeutics platform
Jul 06, 2022: Applied Molecular Transport announces top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 06, 2022: Applied Molecular Transport to report top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 04, 2022: Innovent Phase II ulcerative colitis antibody trial doses first subject
Jun 20, 2022: EMA accepts Sandoz’s application for high concentration of biosimilar
Jun 08, 2022: Prometheus Biosciences provides enrollment update in APOLLO-CD and ARTEMIS-UC global phase 2 Studies
May 31, 2022: Biora Therapeutics shares presentation of patient data establishing correlation between drug levels in colon and patient outcomes in ulcerative colitis
May 27, 2022: The lancet publishes results from phase 3 induction and maintenance programs evaluating Upadacitinib (RINVOQ) in ulcerative colitis
May 24, 2022: InDex Pharmaceuticals to exhibit at Digestive Disease Week
May 24, 2022: Pfizer presents ELEVATE pivotal findings demonstrating etrasimod’s potentially best-in-class profile in ulcerative colitis
May 24, 2022: Fifty percent of patients with ulcerative colitis treated with Mirikizumab achieved clinical remission at one year in Lilly's pivotal phase 3 study
May 24, 2022: Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate AVT04 and reference product Stelara
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ulcerative Colitis - Dormant Projects, 2022
Ulcerative Colitis - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications